A 2026 outlook on Daebong LS (078140), the Korean amino-acid API maker whose fermentation and synthesis know-how feeds both pharmaceutical manufacturers and, through Jeju-sourced natural ingredients, the K-beauty supply chain, covering its in-house clinical testing subsidiary, global GMP path, and risks.
Hyundai Bioland (KOSDAQ 052260) stock outlook 2026: a qualitative deep dive into hyaluronic acid and collagen ingredient localization, its supply role feeding Cosmax and Kolmar ODM lines, the Hyundai Department Store Group ownership angle, and microbiome upside.
Cosmax BTI (044820) 2026 stock outlook. A deep look at the Cosmax Group holding company: how its stake in listed operating unit Cosmax (192820) and health-supplement maker Cosmax NBT drives net-asset value, why holdco discounts persist, dividend flow, dual-listing risk, and how it differs from the operating company itself.
A 2026 outlook on Korea Cosmetics Manufacturing (003350): why it is a cosmetics ODM and OEM manufacturer rather than a brand, how it differs from the separately listed seller Korea Cosmetics (123690), the reality of K-beauty export spillover, small-float volatility, peer comparison, and a practical playbook for investors.
Kolmar Holdings (KRX 024720, formerly Kolmar Holdings Korea) 2026 stock outlook. A qualitative look at the pure holding company controlling Kolmar Korea's cosmetics ODM export boom and HK inno.N's K-CAB pharma pipeline, the persistent Korean holding-company discount, and what US and global investors should weigh before buying this KRX parent ticker.
Pumtech Korea (251970) 2026 stock outlook. A qualitative deep dive into its cosmetic pump, airless dispenser and packaging business, the K-beauty indie-brand export boom, dispensing know-how as a moat, and the real risks of customer concentration and beauty fashion cycles.
Tonymoly (KRX 214420) 2026 stock analysis: the collapse of the single-brand road-shop model, the rebuild through Amazon and Costco in the US plus Japan and Southeast Asia, ODM and A2Gen probiotics diversification, K-beauty export tailwinds, and brand-aging turnaround risk.
I Family SC (KOSDAQ 114840) 2026 stock outlook. A deep, qualitative look at the rom&nd color cosmetics brand, its top-tier position in Japan, expansion across Southeast Asia and the US, the asset-light indie ODM model, Olive Young and cross-border channels, and the single-brand concentration and K-beauty trend-cycle risks.
Able CnC (KOSDAQ 078520) 2026 stock outlook. A deep look at the MISSHA and A'PIEU brand rebrand, the shift from single-brand road shops to Olive Young health-and-beauty, online and Japan exports, structural road-shop decline, the IMM PE ownership overhang, valuation and margin volatility, benchmarked against Clio and Tonymoly.
Manyo Factory (KOSDAQ 439090) 2026 stock outlook. A qualitative deep dive into its vegan clean-beauty brand equity and Pure Cleansing Oil hero product, Japan, US and Southeast Asia export channels, asset-light ODM model, reliance on distributors like Silicon2, and marketing-spend and beauty-trend risks for global investors.
Amorepacific Group (KOSPI 002790) 2026 outlook for foreign investors. How the holding company differs from operating co 090430, the China and duty-free deleveraging, the US and Japan rebalancing, the Cosrx acquisition, Sulwhasoo and Laneige brand equity, and the NAV discount debate.
VT Cosmetics (KOSDAQ 018290) 2026 stock analysis: Reedle Shot brand strength, explosive Japan and Amazon indie-beauty export growth, Olive Young channel, single-hit-product dependence, cosmetics trend risk, and the entertainment segment — from a global investor's view.
Aekyung Industrial (KOSPI: 018250) 2026 stock analysis for global investors: the AGE 20's cosmetics franchise reducing its China export dependence and rebranding, the Kerasys, 2080, and Trio household-goods cash cow, domestic consumption, raw-material and currency exposure, LINE Friends and IP collaborations, the beauty-segment rebound scenario, and Aekyung Group risk.
Cosmecca Korea (KOSDAQ: 241710) 2026 stock analysis: the cosmetics ODM/OEM manufacturing engine behind the K-beauty and indie-brand export boom, the strategic value of US subsidiary Englewood Lab and its onshore American production, the split US-China-Korea manufacturing base, customer diversification, and the input-cost, FX, and tariff variables that drive margins — analyzed qualitatively for global investors.
CLIO (KOSDAQ 237880) 2026 stock analysis: Peripera, Goodal, and CLIO brand portfolio, Olive Young H&B channel plus online and global (Japan, US Amazon) expansion, indie-brand competition, cost and marketing structure, and channel-dependence, China-exposure, and trend-sensitivity risks.
APR Corp (KRX 278470) 2026 stock outlook. A qualitative deep dive into its beauty-tech model that fuses home beauty devices (Medicube AGE-R) with skincare brands, the razor-and-blade device-plus-consumables revenue engine, high-growth global expansion via Amazon and direct-to-consumer in the US and Japan, marketing-spend and trend-dependency risks, and the valuation compression danger baked into a growth premium.
Silicon2 (KRX 257720) 2026 stock outlook for global investors. A qualitative deep dive into the StyleKorean reverse-cross-border platform and the global K-beauty export boom: indie-brand distribution across the US, Middle East, and Europe, logistics infrastructure, brand and fad concentration risk, high-growth high-valuation volatility, currency tailwinds, and how it compares with cosmetics and distribution peers.
Cosmax (KRX: 192820) 2026 stock analysis: the world-leading cosmetics ODM's formulation and R&D moat, the K-beauty indie brand trickle-down effect, production hubs in China, the US, Indonesia, and Thailand, China risk, cost and FX pressure, a Kolmar Korea comparison, and how global investors should frame this picks-and-shovels cosmetics play.
Kolmar Korea (KRX 161890) 2026 stock outlook. A qualitative analysis of Korea's No.1 cosmetics ODM/OEM, its direct leverage to the indie K-beauty export boom, US and China manufacturing bases, pharma CMO operations, and its HK inno.N (K-CAB) subsidiary engine. We also cover demand-cycle, customer-brand dependence, China, and FX risks for global investors.
LG Household & Health Care (051900) 2026 stock analysis: three divisions — Beauty (The History of Whoo luxury cosmetics), Home & Daily Beauty, and Coca-Cola Korea bottling. China demand recovery, duty-free/daigou normalization, Whoo brand reset, dividend, and why this de-rated compounder cushions cosmetics cyclicality with stable beverage cash flow.